BioClinica^®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced its partnership with NextDocs, a leading global provider of Microsoft SharePoint-based compliance solutions to life sciences organizations, to deliver solutions that provide easier access to clinical trial information and decrease the timeline for FDA submissions.

Through this strategic partnership, the two companies will extend integration that unites BioClinica’s OnPoint Clinical Trial Management System (CTMS) and NextDocs’ Electronic Trial Master Form (eTMF) products.

“Our competitive success worldwide, especially in Europe, demonstrates the value of collaborative partnerships like this that make BioClinica the clinical trial solutions provider-of-choice for top-tier pharmaceutical companies.”

BioClinica’s OnPoint CTMS helps clinical trial sponsors and CROs to efficiently access, share, and analyze operational data by leveraging the power and ease of use of Microsoft SharePoint. NextDocs’ eTMF provides customers a comprehensive document repository that simplifies the management of essential trial documentation and is compliant with the established Drug Information Association (DIA) reference model.

The unification of these industry-leading systems creates a highly flexible workflow that reduces duplicate efforts and creates a seamless system for trial management and regulatory document routing.

For example, as new trial sites are qualified for trial participation in BioClinica OnPoint, NextDocs’ eTMF will automatically create the required regulatory document lists for the site. As these documents are reviewed, they are automatically submitted into the NextDocs workflow where they are routed for review and approval, signed off electronically, and formatted for submission to the FDA.

OnPoint CTMS and NextDocs eTMF can also be deployed to the same SharePoint portal and sub-sites. This solution allows trial sponsors to access their study information through a single Microsoft SharePoint 2010 site. Trial managers can access eTMF documents, see document collection and approval status, and perform CTMS functions, such as review subject enrollment information and site monitoring reports, all in the same place.

“As a company focused on advancing the field of clinical research, BioClinica is excited to partner with a leader like NextDocs and bridge the gap between CTMS and eTMF systems,” said Peter Benton, BioClinica’s President of eClinical Solutions.

“Our competitive success worldwide, especially in Europe, demonstrates the value of collaborative partnerships like this that make BioClinica the clinical trial solutions provider-of-choice for top-tier pharmaceutical companies.”

“This partnership brings to the life sciences industry critical advances to simplify and accelerate business processes,” said Zikria Syed, Chief Executive Officer of NextDocs.

“BioClinica is one of the top eClinical firms supporting global biopharmaceutical and medical device development, and we’re pleased to work with them. Together, we’ll help our mutual clients more effectively and efficiently manage clinical trial workflows.”

Both BioClinica and NextDocs are Microsoft Gold-Certified partners. BioClinica has long been known for its industry-leading integration with Microsoft technology, harnessing the power of SharePoint and the Microsoft Office Suite to provide study project managers a comprehensive, real-time view into trial performance.

NextDocs is the global leader in Microsoft SharePoint-based compliance solutions for life sciences organizations.

BioClinica will next demonstrate its eClinical solutions at DIA EuroMeeting March 26 – 28, 2012 in Copenhagen, Denmark at Booth 138. Recent releases of BioClinica’s OnPoint CTMS, Trident IWR, and Express EDC have experienced significant growth and adoption across the United States, Europe, and Asia, including multiple contracts with major European biopharma and research organizations.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions.

BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval.

BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

About NextDocs Corporation

NextDocs is the global leader in providing Microsoft SharePoint-based compliance software solutions including quality management software, regulatory document management, and clinical portals. Its solutions enable businesses in regulated industries to achieve compliance with FDA and other agencies while automating processes, improving efficiency, and dramatically reducing costs.

NextDocs customers include pharmaceutical companies, bio-techs, medical device companies, and CROs. For more information on NextDocs Corporation and the software solutions visit www.nextdocs.com.

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements.

The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.

The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements.

The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

Contacts

ExactTarget (NYSE: ET), a global provider of cross-channel interactive marketing solutions, opened for trading today on the New York Stock Exchange (NYSE) under the ticker symbol “ET” after its initial public offering.

“We’re honored to join the NYSE family and look forward to the new opportunities this creates to help marketers around the world leverage the power of cross-channel interactive marketing.”

NYSE Euronext welcomed ExactTarget on its first day by enveloping the NYSE in a sea of “orange” – ExactTarget’s signature color representing the company’s unique corporate culture. Orange exuded throughout the building, from the backdrop and images on the bell podium where CEO Scott Dorsey rang The Opening Bell^SM to mark the company’s first day of trading, to the orange-carpeted path leading from the bell podium to ExactTarget’s stock location on the trading floor.

NYSE traders and ExactTarget employees marked the occasion by sporting orange jackets with ExactTarget’s NYSE ticker symbol. The orange theme extended to the NYSE façade, adorned with a large ExactTarget banner which greeted NYSE guests, employees and the Wall Street community.

“ExactTarget is a leading Software as a Service provider offering companies around the globe a suite of innovative tools to effectively communicate with customers,” said Scott R. Cutler, EVP and Co-Head of U.S. Listings and Cash Equities, NYSE Euronext.

“We are thrilled to welcome ExactTarget to our growing community of technology-based companies, and we look forward to a successful, lasting partnership with the company and its shareholders.”

“The energy and vibrancy of the New York Stock Exchange make this the perfect location to begin our next chapter of growth and innovation,” said Scott Dorsey, ExactTarget co-founder and chief executive officer.

“We’re honored to join the NYSE family and look forward to the new opportunities this creates to help marketers around the world leverage the power of cross-channel interactive marketing.”

About ExactTarget

ExactTarget is a leading global provider of email marketing and cross-channel interactive marketing software-as-a-service solutions that empower organizations of all sizes to communicate with their customers through email, mobile, social media and websites.

ExactTarget’s powerful suite of integrated applications enable marketers to plan, automate, deliver and optimize data-driven interactive marketing and real-time communications to drive customer engagement, increase sales and improve return on marketing investment. For more information, visit www.ExactTarget.com. (Source: ExactTarget)

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company’s exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext’s equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world’s equities trading, the most liquidity of any global exchange group.

NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world’s second-largest derivatives business by value of trading.

The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit: http://www.nyx.com.

Disclaimer and Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext’s plans, objectives, expectations and intentions and other statements that are not historical or current facts.

Forward-looking statements are based on NYSE Euronext’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements.

Factors that could cause NYSE Euronext’s results to differ materially from current expectations include, but are not limited to: NYSE Euronext’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext’s 2011 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers.

In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct.

This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50214998&lang=en

Contacts

NextDocs Corporation will unveil the company’s latest Microsoft SharePoint-based compliance and collaboration software for life sciences companies.

An updated release of NextDocs for SharePoint 2010, including major regulatory additions, will be demonstrated live at booth #405 during the 24th Annual DIA EuroMeeting. The conference is being held at the Bella Center in Copenhagen, Denmark from March 26-28, 2012.

“There is more pressure on life sciences companies to move quickly when initiating and managing clinical trials, which makes quality, compliance, and cost containment a challenge”

NextDocs developed its latest release with the support and input of life sciences executives, SharePoint aficionados and recognized experts from across the industry. NextDocs for SharePoint 2010 software includes enhancements that support global life sciences companies in achieving compliance amidst increased regulatory demands and improve productivity among clinical study teams.

“There is more pressure on life sciences companies to move quickly when initiating and managing clinical trials, which makes quality, compliance and cost containment a challenge,” says Zikria Syed, Chief Executive Officer of NextDocs.

“Global collaboration and regulatory compliance is easier and more efficient with NextDocs solutions that address a broad range of demands on life sciences companies. We’re making it easier too. DIA EuroMeeting offers NextDocs the opportunity to showcase our solution to European customers as Software as a Service (SAAS) via the NextDocs private Cloud.”

The new software adds:

• Complete document relationship functionality for global regulatory collaboration
• Reference Model foundation, which can be adapted and expanded through configuration to meet the specific needs for pharmaceutical, biotech, CRO, and other life sciences companies
• Innovative features such as automatic generation of investigator and site documents from metadata, “IP Greenlight” (automatic checking of the availability of country-specific documents allowing shipment of the investigational product)

Attendees of the DIA EuroMeeting conference can learn more about NextDocs solutions by stopping by booth #405. NextDocs representatives will be available to discuss how the company’s software can enhance Regulatory Document Management, SOPs and Quality Management Systems, as well as how organizations can achieve compliance, quality and productivity.

The EuroMeeting attracts more than 3,000 professionals from over 50 countries. It brings together professionals from the biopharmaceutical industry, contract service organizations, clinical research, regulatory agencies, health ministries, patients’ organizations and universities. This convergence affords attendees the opportunity to network with professional colleagues from around the world.

About NextDocs

NextDocs is the global leader in Microsoft SharePoint-based document and quality management solutions to life science organizations. It enables businesses in regulated industries to achieve compliance with regulatory agencies while automating processes, improving efficiency and dramatically reducing costs.

NextDocs has enjoyed significant growth in Europe. With four offices located now open, NextDocs is committed to providing strong support to its European customers while further expanding its base in the region, adding to their well established customer base in seven countries.

For more information on NextDocs Corporation and its software solutions visit www.nextdocs.com.

Contacts

eEye Digital Security, the industry’s leading innovator of threat management solutions, today released a new configuration-check tool based on new research, “In Configuration We (Still) Trust.”

Findings verify that proper configuration and mitigations remain the most effective way to secure IT infrastructure.

The research team at eEye found that the leading mitigations it recommended in 2011 — disabling WebDAV and Microsoft Office document converters — prevented even more vulnerabilities in 2011 than in 2010. In the case of turning off the Office document converters, the percentage increased from eight to 10 percent. Combined, the two tactics mitigate 20 percent of Microsoft vulnerabilities.

To put these relatively simple recommendations into action, IT administrators can download a new, free security tool developed by the eEye Research Team. It tests for highly recommended configuration updates and:

• Offers a simple pass/fail and informational status check to compare how the user’s company rates against recommended configurations
• Tests how the local system operating system is configured and how the network is architected, identifying potential problem areas
• Provides information on potential backdoors and other areas of concern related to Advanced Persistent Threats (APT)
• Shows how much of the user’s processes and code are signed, allowing users to determine what is valid and what is not

“eEye prides itself on helping our customers and the security community at large by providing security in context,” said Marc Maiffret, eEye cofounder and CTO.

“With this research and the related free tool, organizations large and small can now quickly test individual systems, gold disks and standard corporate images for some of the most impactful configuration settings from a vulnerability and exploitation perspective.”

The research also shows that in addition to upgrading and disabling WebDAV and Office converters, users should limit administrative privileges, put proxy servers to work, encrypt traffic on VLANs and IPsec, and deny access to Windows subsystems. Additional recommendations, most of which are easy fixes, are noted in the research, including how to protect against threats such as Stuxnet, Night Dragon and Aurora.

Tweet this: The research team at @eEye releases free tool to test & mitigate biggest security holes via smarter config http://eeye.co/icwt12 #infosec

About eEye Digital Security

Since 1998, eEye Digital Security has made vulnerability and compliance management simpler and more efficient by providing the only unified solution that integrates assessment, mitigation, protection, and reporting into a complete offering with optional add-on modules for configuration compliance, regulatory reporting, and integrated patch management.

eEye’s world-renowned research and development team is consistently the first to uncover critical vulnerabilities and build new protections into our solutions to prevent their exploit. Thousands of mid-to-large-size private sector and government organizations, including the largest vulnerability management installations in the world, rely on eEye to protect against the latest known and zero-day vulnerabilities.

Retina CS recently was awarded a five-start “Best Buy” rating in Vulnerability Assessment solutions from SC Magazine. The review can be seen at http://blog.eeye.com/general/sc-magazine-5-star-award.

Balihoo (www.balihoo.com), the premier provider of Local Marketing Automation (LMA) technology and services to national brands with local marketing needs, today announced that CEO Pete Gombert will be speaking at ILM (Interactive Local Media) East 2012 in Boston.

What: 

Panel Discussion: National Advertisers, Targeting Locally

When/Where:

ILM East 2012, March 26 – 28^th, Boston Marriot Hotel, Copley Place

Gombert will speak at 2:15 p.m. on Tuesday, March 27^th

Pete Gombert is available for press interviews. For media inquiries, please contact: Tom Francoeur by email at[email protected], or by phone at 781-404-2405.

About Balihoo

Balihoo is the premier provider of Local Marketing Automation (LMA) technology and services to national brands with local marketing needs. By automating local marketing, Balihoo gives national brands unprecedented control over local marketing execution and the ability to control the customer experience closer to the point of purchase. Additional information about Balihoo is available at www.balihoo.com.

Contacts